A PAROXETINE- AND PLACEBO-CONTROLLED STUDY OF 50 MG/DAY AND 100 MG/DAY OF EB-1010 AMONG OUTPATIENTS WITH MAJOR DEPRESSIVE DISORDER WHO HAVE RESPONDED INADEQUATELY TO PRIOR SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) AND SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS):